Page 2 - அலுவலகம் ஆஃப் ஆர்ஃபந் ப்ராடக்ட்ஸ் வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). This work was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine. Additionally, the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted the Company an orphan drug designation (ODD) to C-CAR039, for the treatment of follicular lymphoma, an indolent form of Non-Hodgkin s Lymphoma.

United statesTony bizuo liuAibin liangKaplan meyerSarah kellyCommunications investor relationsAmerican society of clinical oncologyCompany contactDrug administrationTongji university school of medicineProfessor of department hematologyOffice of orphan products developmentClinical oncologyAnnual meetingPrincipal investigatorShanghai tongji hospital